July 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Alzheimer Disease
June 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Lecanemab Gets Priority Review for Early Alzheimer Disease
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
Crenezumab Misses Endpoints in Autosomal Dominant Alzheimer Disease Trial
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Reductions in Amyloid Beta Plaques, P-Tau Seen With Aducanumab Over 2 Years Later
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Donepezil Transdermal Patch Approved for Alzheimer Disease
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.
Ethical Considerations Explored for Aducanumab in Alzheimer Disease
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Aducanumab Significantly Reduces Tau Pathology, Clinical Decline in Alzheimer Disease
New data evaluating the treatment effect of aducanumab-avwa demonstrated a positive correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer disease.
